A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
about
Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.
P2860
A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A phase II clinical trial of w ...... triple negative breast cancer.
@ast
A phase II clinical trial of w ...... triple negative breast cancer.
@en
type
label
A phase II clinical trial of w ...... triple negative breast cancer.
@ast
A phase II clinical trial of w ...... triple negative breast cancer.
@en
prefLabel
A phase II clinical trial of w ...... triple negative breast cancer.
@ast
A phase II clinical trial of w ...... triple negative breast cancer.
@en
P2093
P2860
P1476
A phase II clinical trial of w ...... triple negative breast cancer.
@en
P2093
J A Lawrence
L D Miller
P2860
P304
P356
10.1080/15384047.2015.1026481
P577
2015-01-01T00:00:00Z